Robbins LLP reminds investors that a class action has been filed on behalf of purchasers of Grail, Inc. securities between May 13, 2025 and February 19, 2026. The lawsuit alleges that Grail misled investors about the likelihood of success for its NHS-Galleri trial in achieving a statistically significant reduction in late-stage cancers. On February 19, 2026, the company reported the trial failed to meet its primary endpoint, causing the stock to drop from $101.53 to $50.21 per share, a decline of approximately 50.55% in one day. Shareholders have until August 4, 2026 to seek lead plaintiff status, though participation is not required to be eligible for recovery. Robbins LLP is handling the case on a contingency fee basis.
GRAIL, LLCClass action lawsuit alleges Grail misled investors about NHS-Galleri trial success, and trial failed primary endpoint.